Zusammenfassung
Hintergrund
Etwa 16.000 Menschen erkranken jährlich in Deutschland an einem muskelinvasiven Harnblasenkarzinom. Standardtherapie ist dabei die radikale Zystektomie mit regionaler Lymphadenektomie. Innerhalb der ersten 2 Jahre nach erfolgter Operation erleiden bis zu 50 % der Patienten mit einem initial nicht metastasiertem Tumorstadium T2–T4a Lymphknotenbefall und/oder Fernmetastasen.
Methode
Recherche und Analyse aktueller Literatur.
Ergebnisse
Zur Eliminierung möglicher Mikrometastasen wird heute der Einsatz perioperativer Therapiekonzepte in Form einer neoadjuvanten, induktiven oder adjuvanten Chemotherapie empfohlen. Obwohl der Nutzen einer perioperativen Chemotherapie mit einer Verbesserung der Überlebensrate durch klinische Studien und Metaanalysen klar belegt ist, findet das Verfahren in Europa noch immer nur eine geringe Akzeptanz. Neben der aktuellen Datenlage werden die Vor- und Nachteile der verschiedenen Modalitäten dargestellt und diskutiert.
Abstract
Background
Every year approximately 16,000 patients are diagnosed with muscle-invasive bladder cancer in Germany. The standard procedure in these patients is radical cystectomy with regional pelvic lymphadenectomy. Within the first 2 years after resection up to 50% of patients initially with non-metastatic tumor stages T2–T4a will relapse with lymph node involvement and/or visceral metastases.
Methods
Research and analysis of the current literature.
Results
To eliminate potential micrometastases the use of perioperative therapeutic concepts in the form of neoadjuvant, inductive and adjuvant chemotherapy is strongly recommended. Despite positive results and high-level evidence from several randomized trials and meta-analyses showing an improved overall survival in favour of bladder cancer patients treated with perioperative chemotherapy, the procedure is currently still underused in Europe. In this review the current data and arguments for and against the various modalities are discussed.
Literatur
Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. (Hrsg) (2012) Krebs in Deutschland 2007/2008. Robert Koch-Institut, Berlin
Lynch CFDJ, Platz CE (2007) Cancer of the urinary bladder. In: Ries LAGYJ, Keel GE, Eisner MP, Lin YD, Horner M‑J (Hrsg) Seer survival monograph: Cancer survival among adults: Us seer program, 1988–2001, patient and tumor characteristics national cancer institute, seer program, nih pub no 07-6215. Bethesda, S 181–192
Bellmunt J, Orsola A, Wiegel T, Guix M, De Santis M, Kataja V (2011) Bladder cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi45–49
Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA (2011) Treatment of muscle-invasive and metastatic bladder cancer: Update of the eau guidelines. Eur Urol 59:1009–1018
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (abc) meta-analysis collaboration. Eur Urol 48(2):202–205. https://doi.org/10.1016/j.eururo.2005.04.006 (discussion 205–206)
Raj GV, Karavadia S, Schlomer B, Arriaga Y, Lotan Y, Sagalowsky A, Frenkel E (2011) Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. Cancer 117:276–282
Burger M, Mulders P, Witjes W (2012) Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major european centres: results of a feasibility questionnaire. Eur Urol 61:1070–1071
Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF (2008) A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 113(9):2471–2477. https://doi.org/10.1002/cncr.23848
Hupe MC, Kramer MW, Kuczyk MA, Merseburger AS (2015) [Neoadjuvant or Adjuvant chemotherapy for bladder cancer?]. Aktuelle Urol 46(3):242–247. https://doi.org/10.1055/s-0035-1549948
Meijer RP, Mertens LS, van Rhijn BW, Bex A, van der Poel HG, Meinhardt W, Kerst JM, Bergman AM, Fioole-Bruining A, van Werkhoven E, Horenblas S (2014) Induction chemotherapy followed by surgery in node positive bladder cancer. Urology 83(1):134–139. https://doi.org/10.1016/j.urology.2013.08.082
International collaboration of trialists (1999) Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354:533–540
Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK (2011) International phase iii trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the ba06 30894 trial. J Clin Oncol 29:2171–2177
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr., Raghavan D, Crawford ED (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859–866
Sherif A, Holmberg L, Rintala E, Mestad O, Nilsson J, Nilsson S, Malmstrom PU (2004) Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two nordic studies. Eur Urol 45:297–303
Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602–4608
Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ (2016) Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 21(6):708–715. https://doi.org/10.1634/theoncologist.2015-0440
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 361(9373):1927–1934
Winquist E, Kirchner TS, Segal R, Chin J, Lukka H (2004) Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 171:561–569
Lawrentschuk N, Colombo R, Hakenberg OW, Lerner SP, Mansson W, Sagalowsky A, Wirth MP (2011) Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol 57:983–1001
European Organization for Research on Treatment of Cancer–Genitourinary Group, Splinter TA, Scher HI, Denis L, Bukowski R, Simon S, Klimberg I, Soloway M, Vogelzang NJ, van Tinteren H, Herr H (1992) The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. J Urol 147(3):606–608
Canter D, Viterbo R, Kutikov A, Wong YN, Plimack E, Zhu F, Oblaczynski M, Berberian R, Chen DY, Greenberg RE, Uzzo RG, Boorjian SA (2011) Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 77:160–165
Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF (2008) A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 113(9):2471–2477. https://doi.org/10.1002/cncr.23848
Hoffmann AC, Wild P, Leicht C, Bertz S, Danenberg KD, Danenberg PV, Stohr R, Stockle M, Lehmann J, Schuler M, Hartmann A (2010) Mdr1 and ercc1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12:628–636
Goldie JH (1987) Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 14:1–7
Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF (2016) Leitlinienprogramm Onkologie: S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. http://www.awmf.org/uploads/tx_szleitlinien/032-038ol_l_S3_Harnblasenkarzinom_2016-12.pdf
Wiesner C, Salzer A, Thomas C, Gellermann-Schultes C, Gillitzer R, Hampel C, Thuroff JW (2009) Cancer-specific survival after radical cystectomy and standardized extended lymphadenectomy for node-positive bladder cancer: prediction by lymph node positivity and density. BJU Int 104:331–335
Bruins HM, Huang GJ, Cai J, Skinner DG, Stein JP, Penson DF (2009) Clinical outcomes and recurrence predictors of lymph node positive urothelial cancer after cystectomy. J Urol 182:2182–2187
Osawa T, Abe T, Shinohara N, Harabayashi T, Sazawa A, Kubota K, Matsuno Y, Shibata T, Shinno Y, Kamota S, Minami K, Sakashita S, Kumagai A, Mori T, Nonomura K (2009) Role of lymph node density in predicting survival of patients with lymph node metastases after radical cystectomy: a multi-institutional study. Int J Urol 16:274–278 (discussion 278)
Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A, ESMO Guidelines Working Group (2014) Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii40–iii48. https://doi.org/10.1093/annonc/mdu223
Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, Neuzillet Y, Veskimäe E, van der Heijden AG, Gakis G, Ribal MJ (2017) Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 71(3):462–475. https://doi.org/10.1016/j.eururo.2016.06.020
Pas-Arez LGS, Solsona E, Esteban E, Saez A, Gonzalez-Larriba J, Anton A, Hevia M, De la Guillem Bellmunt RFFJ (2010) Randomized phase iii trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (pgc) to observation in patients with resected invasive bladder cancer: Results of the spanish oncology genitourinary group (sogug) 99/01 study. J Clin Oncol. https://doi.org/10.1200/jco.2010.28.18_suppl.lba4518
Cognetti F, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, Massidda B, Rubagotti A, Giannarelli D, Boccardo F (2012) Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an italian, multicenter, randomized phase iii trial. Ann Oncol 23:695–700
Sternberg CN, Skoneczna I, Kerst JM et al (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16:76–86
Ohlmann CH, Stöckle M (2015) Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 Urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 2015;16:76–86. Eur Urol 68(6):1104–1105. https://doi.org/10.1016/j.eururo.2015.08.013
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data advanced bladder cancer (abc) meta-analysis collaboration. Eur Urol 48:189–199 (discussion 199–201)
Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, Cote RJ, Urun Y, Chang SL, Choueiri TK, Bellmunt J (2014) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66(1):42–54. https://doi.org/10.1016/j.eururo.2013.08.033
Donat SM, Shabsigh A, Savage C, Cronin AM, Bochner BH, Dalbagni G, Herr HW, Milowsky MI (2009) Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 55(1):177–185. https://doi.org/10.1016/j.eururo.2008.07.018
Rosenblatt R, Sherif A, Rintala E, Wahlqvist R, Ullen A, Nilsson S, Malmstrom PU (2012) Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 61:1229–1238
Frantzi M, Latosinska A, Flühe L, Hupe MC, Critselis E, Kramer MW, Merseburger AS, Mischak H, Vlahou A (2015) Developing proteomic biomarkers for bladder cancer: towards clinical application. Nat Rev Urol 12(6):317–330. https://doi.org/10.1038/nrurol.2015.100
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
A. Lorch: Novartis, AstraZeneca, MSD, BMS, Novartis, Roche, Ipsen; A.S. Merseburger: BMS, Merck/MSD, Roche, Pfizer, Janssen, Astellas, Astra Zeneca, Ipsen, Takeda; C.-H. Ohlmann: Pierre Fabre, BMS, Roche, MSD
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Lorch, A., Merseburger, A.S. & Ohlmann, CH. Perioperative Chemotherapie des Harnblasenkarzinoms. Onkologe 24, 48–54 (2018). https://doi.org/10.1007/s00761-017-0303-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-017-0303-x
Schlüsselwörter
- Muskelinvasives Harnblasenkarzinom
- Perioperative Chemotherapie
- Neoadjuvante Chemotherapie
- Adjuvante Chemotherapie
- Zystektomie